Is BKYI's long-term EPS outlook improving after Q3 2024?

**Bio-key International's (BKYI) long-term EPS outlook appears to be improving after Q3 2024**, based on several key indicators:

1. **Consistent Revenue Growth**: BKYI has shown a consistent increase in revenue over the past quarters, with a notable 17.6% year-over-year growth in Q3 GAAP revenue. This trend suggests a strong market demand for their products and services, which is a positive signal for future earnings potential.
2. **Strategic Initiatives**: The company has been implementing strategic initiatives to expand market presence and improve operational efficiency. These efforts have led to a significant reduction in net loss by 49% to $4.3 million in 2024, indicating a healthier financial trajectory.
3. **License Fee Growth**: BKYI has experienced a 52% increase in license fees for the three months ended September 30, 2024, compared to the same period in 2023. This growth in high-margin software license fees is a positive indicator, as it contributes to the company's overall revenue and profitability.
4. **Hardware Sales Increase**: A 56% increase in hardware sales for the three months ended September 30, 2024, compared to the same period in 2023 further supports the notion of improving revenue streams. Hardware sales are often associated with higher upfront costs but can lead to sustained revenue over time through software upgrades and maintenance.
5. **Financial Ratios Improvement**: The company's financial ratios are showing improvements, such as a higher gross margin and reduced operating costs. These improvements are likely to translate into better net income margins over time, positively impacting EPS.

In conclusion, while BKYI has faced challenges in the past, the company's strategic shifts, revenue growth, and operational improvements suggest that its long-term EPS outlook is heading in a positive direction after Q3 2024.